Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. The core difference is the number of receptors each peptide is designed to interact with.
Side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Type | Single agonist | Dual agonist |
| Receptors targeted | GLP-1 | GIP and GLP-1 |
| Family | GLP-1 receptor peptides | GLP-1 receptor peptides |
| Research area | Metabolic research | Metabolic research |
| Status | Research use only | Research use only |
Same family, different reach
Both belong to the GLP-1 receptor peptide family. The trend across the family runs from single to dual to triple agonists, with Retatrutide adding a third target. Whichever compound you study, look for a documented certificate of analysis.
Key takeaways
- Semaglutide is a single GLP-1 receptor agonist.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist.
- The core difference is the number of receptors targeted.
- Both are research compounds, supplied for research use only.
A note on research use
The peptides supplied by Axis Peptide Labs are reference compounds for laboratory and research use only. They are intended for qualified researchers working in academic, institutional, and analytical settings. They are not drugs, foods, cosmetics, or medical products, and they are not intended for human or veterinary consumption. Documented identity and documented purity are what matter most when sourcing a compound, both of which are published on the Axis certificates of analysis page.
